A drug called daraxonrasib is being studied for its potential to treat pancreatic cancer, with some reports suggesting it may improve survival rates. The drug, a RAS inhibitor, has shown promise in clinical trials, particularly for patients with metastatic pancreatic adenocarcinoma who have been previously treated. Its potential impact and next steps, including possible FDA approval and compassionate use, are being discussed by medical experts and organizations.